ReviewFrontiers in immunology2022
Occurrence and role of lung megakaryocytes in infection and inflammation.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Hematopoietic JAK2V617F mutation-induced reprogramming of blood and bone marrow megakaryocytes.Blood advances · 2026Article
- The alarmin interleukin-33 modulates platelet proteome, function, and biogenesis.Blood advances · 2026Article
- Platelet-like particles released from Ebola virus-infected megakaryocytic cells behave like virus-like particles.PLoS pathogens · 2026Article
- Beyond Thrombopoiesis: The Immune Functions of Megakaryocytes in Bacterial Infections and Sepsis.International journal of molecular sciences · 2025Review
- Altered thrombopoiesis in spontaneously hypertensive rats.Scientific reports · 2025Article
- Emerging Roles of Megakaryocytes in Immune Regulation and Potential Therapeutic Prospects.Cells · 2025Review
- Article
- α-Actinin-1 deficiency in megakaryocytes causes low platelet count, platelet dysfunction, and mitochondrial impairment.Blood advances · 2025Article
- Immune dysregulation in COVID-19 induced ARDS in kidney transplant recipients revealed by single-cell RNA sequencing.Scientific reports · 2025Article
- Cause of Death Analysis in a 9½-Year-Old with COVID-19 and Dravet Syndrome.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Article
- Friend or foe: the role of platelets in acute lung injury.Frontiers in immunology · 2025Review
- Research progress of megakaryocytes and platelets in lung injury.Annals of medicine · 2024Review
- The lung is a megakaryocyte outpost that can defend against thrombocytopenic attack.The Journal of clinical investigation · 2024Article
- Time-Dependent Changes in Pulmonary Turnover of Thrombocytes During Critical COVID-19.Critical care explorations · 2024Article
- Review
- HMGA2 promotes platelet-neutrophil complex formation and pulmonary tissue damage in myelodysplastic syndromes.Blood vessels, thrombosis & hemostasis · 2024Article
- AC-73 and Syrosingopine Inhibit SARS-CoV-2 Entry into Megakaryocytes by Targeting CD147 and MCT4.Viruses · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Megakaryocytes (MKs) are large cells giving rise to platelets. It is well established that in adults, MKs develop from hematopoietic stem cells and reside in the bone marrow. MKs are also rare but normal constituents of the venous blood returning to the lungs, and MKs are found in the lung vasculature (MK
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.